Accueil   Diary - News   All news Erytech announces ADR level 1 Listing in the US

Erytech announces ADR level 1 Listing in the US

ERYTECH,the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.

 

Read the press release